Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beamion PANTUMOR-1: Zongertinib in HER2-altered Solid Tumours
NCT06581432Phase 2Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Primary completion
- Nov 2028
- Countries
- 16
01
Overview
A Phase 2 trial of zongertinib in solid tumor, sponsored by Boehringer Ingelheim. Started Oct 2024; status: recruiting.
02
Drugs
zongertinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06581432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06581432.